Prodrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38

Journal of Controlled Release

Volumn 172, Issue 1, 2013, Pages 48-61

  Bala, Vaskor ^a   Rao, Shasha ^a   Boyd, Ben J ^b   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b MONASH UNIVERSITY   (Australia)

Author keywords

7 Ethyl 10 hydroxy camptothecin; Macromolecule; Polymer drug conjugate; Targeted delivery

Indexed keywords

ANTI-CANCER AGENTS; CAMPTOTHECIN (CPT); DIRECT FORMULATION; LIPID NANOCAPSULES; PHYSIOLOGICAL ENVIRONMENT; POLYMER DRUGS; TARGETED DELIVERY; WATER-SOLUBLE PRODRUGS;

BODY FLUIDS; CHEMOTHERAPY; HISTOLOGY; LIPOSOMES; MACROMOLECULES; MICELLES; TISSUE;

MEDICAL NANOTECHNOLOGY;

DENDRIMER; FIRTECAN; FIRTECAN GLUCURONIDE; FIRTECAN PEGOL; IRINOTECAN; LIPOSOME; NANOCAPSULE; NANOPARTICLE; PRODRUG; TENIFATECAN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; DTS 108; GLYCOLIC ACID; IMMU 130; NANOCARRIER; UNCLASSIFIED DRUG;

CANCER CELL; CANCER TISSUE; DRUG DELIVERY SYSTEM; DRUG RELEASE; ENZYME PRODRUG THERAPY; HUMAN; HYDROGEL; NANOEMULSION; NANOMEDICINE; NONHUMAN; PHYSICAL CHEMISTRY; POLYMERIZATION; PRIORITY JOURNAL; REVIEW; 7-ETHYL-10-HYDROXY CAMPTOTHECIN; ANIMAL; CHEMISTRY; MACROMOLECULE; METHODOLOGY; NEOPLASM; POLYMER DRUG CONJUGATE; TARGETED DELIVERY; AREA UNDER THE CURVE; BIOENGINEERING; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CONJUGATE; DIARRHEA; DRUG CYTOTOXICITY; DRUG FORMULATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG PENETRATION; IC 50; LIPOPHILICITY; LIPOSOMAL DELIVERY; MICELLE; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); SUSTAINED DRUG RELEASE;

7-ETHYL-10-HYDROXY CAMPTOTHECIN; MACROMOLECULE; POLYMER DRUG CONJUGATE; TARGETED DELIVERY;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; DRUG DELIVERY SYSTEMS; HUMANS; NANOMEDICINE; NEOPLASMS; PRODRUGS;

EID: 84883508947     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2013.07.022     Document Type: Review

References (111)

1. M.C. Wani, P.E. Ronman, J.T. Lindley, and M.E. Wall Plant antitumor agents. 18. Synthesis and biological activity of camptothecin analogs J. Med. Chem. 23 1980 554 560 (Pubitemid 10153550)
2. J.A. Gottlieb, A.M. Guarino, J.B. Call, V.T. Oliverio, and J.B. Block Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880) Cancer Chemother. Rep. 1 54 1970 461
3. F.M. Muggia, P. Creaven, H. Hansen, M. Cohen, and O. Selawry Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies Cancer Chemother. Rep. 1 56 1972 515
4. 6,8-tetrahydroindolizine: total synthesis and antitumor activity of 20(S)- and 20(R)-camptothecin J. Med. Chem. 30 1987 2317 2319 (Pubitemid 17167484)
5. Q. Li, X.-q. Deng, Y.-g. Zu, H. Lv, L. Su, L. Yao, Y. Zhang, and L. Li Cytotoxicity and Topo I targeting activity of substituted 10 - nitrogenous heterocyclic aromatic group derivatives of SN-38 Eur. J. Med. Chem. 45 2010 3200 3206
6. H. Ulukan, and P.W. Swaan Camptothecins: a review of their chemotherapeutic potential Drugs 62 2002 2039 2057 (Pubitemid 35204037)
7. R. Garcia-Carbonero, and J.G. Supko Current perspectives on the clinical experience, pharmacology, and continued development of the camptothecins Clin. Cancer Res. 8 2002 641 661 (Pubitemid 34742090)
8. Y.H. Hsiang, R. Hertzberg, S. Hecht, and L. Liu Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I J. Biol. Chem. 260 1985 14873 14878 (Pubitemid 16211028)
9. A. Tanizawa, A. Fujimori, Y. Fujimori, and Y. Pommier Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials J. Natl. Cancer Inst. 86 1994 836 842 (Pubitemid 24164661)
10. M.E. Wall, M.C. Wani, C.E. Cook, K.H. Palmer, A.T. McPhail, and G.A. Sim Plant antitumor agents. I. The isolation and structure of camptothecin, a novel alkaloidal leukemia and tumor inhibitor from Camptotheca acuminata1,2 J. Am. Chem. Soc. 88 1966 3888 3890
11. A. Tanizawa, K.W. Kohn, G. Kohlhagen, F. Leteurtre, and Y. Pommier Differential stabilization of eukaryotic DNA topoisomerase I cleavable complexes by camptothecin derivatives Biochemistry 34 1995 7200 7206
12. T.G. Burke, and Z. Mi Ethyl substitution at the 7 position extends the half-life of 10-hydroxycamptothecin in the presence of human serum albumin J. Med. Chem. 36 1993 2580 2582 (Pubitemid 23270812)
13. R. Thakur, B. Sivakumar, and M. Savva Thermodynamic studies and loading of 7-ethyl-10-hydroxycamptothecin into mesoporous silica particles MCM-41 in strongly acidic solutions J. Phys. Chem. B 114 2010 5903 5911
14. B. Sivakumar Physico-chemical Characterization of 7-Ethyl-10-Hydroxy Camptothecin (SN38) and Formulation Approaches Towards Improving its Solubility and Solution Stability 2010 Long Island University, The Brooklyn Center New York, United States
15. E. Roger, F. Lagarce, and J.-P. Benoit Development and characterization of a novel lipid nanocapsule formulation of SN38 for oral administration Eur. J. Pharm. Biopharm. 79 2011 181 188
16. P. Sapra, H. Zhao, M. Mehlig, J. Malaby, P. Kraft, C. Longley, L.M. Greenberger, and I.D. Horak Novel delivery of SN38 markedly inhibits tumor growth in xenografts, including a camptothecin-11 - refractory model Clin. Cancer Res. 14 2008 1888 1896 (Pubitemid 351469476)
17. J.A. Zhang, T. Xuan, M. Parmar, L. Ma, S. Ugwu, S. Ali, and I. Ahmad Development and characterization of a novel liposome-based formulation of SN-38 Int. J. Pharm. 270 2004 93 107 (Pubitemid 38077091)
18. X. Wang, X. Zhou, and S.M. Hecht Role of the 20-hydroxyl group in camptothecin binding by the topoisomerase I - DNA binary complex† Biochemistry 38 1999 4374 4381
19. R. Thakur Preformulation Studies and Development of MCM-41-7-ethyl-10- hydroxycamptothecin-loaded Particles for Drug Delivery 2011 Long Island University, The Brooklyn Center United States, New York
20. Pfizer Injectables U.S. Physician Prescribing Information for CAMPTOSAR (Irinotecan HCl injection) 2010
21. F. Koizumi, M. Kitagawa, T. Negishi, T. Onda, S.-i. Matsumoto, T. Hamaguchi, and Y. Matsumura Novel SN-38-incorporating polymeric micelles, NK012, eradicate vascular endothelial growth factor-secreting bulky tumors Cancer Res. 66 2006 10048 10056 (Pubitemid 44672058)
22. D. Abigerges, G.G. Chabot, J.P. Armand, P. Hérait, A. Gouyette, and D. Gandia Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients J. Clin. Oncol. 13 1995 210 221
23. E. Gupta, R. Mick, J. Ramirez, X. Wang, T.M. Lestingi, E.E. Vokes, and M.J. Ratain Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients J. Clin. Oncol. 15 1997 1502 1510 (Pubitemid 27167386)
24. G. Catimel, G.G. Chabot, J.P. Guastalla, A. Dumortier, C. Cote, C. Engel, A. Gouyette, A. Mathieu-Boué, M. Mahjoubi, and M. Clavel Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every three weeks in patients with advanced solid tumors Ann. Oncol. 6 1995 133 140
25. L.P. Rivory, M.C. Haaz, P. Canal, F. Lokiec, J.P. Armand, and J. Robert Pharmacokinetic interrelationships of irinotecan (CPT-11) and its three major plasma metabolites in patients enrolled in phase I/II trials Clin. Cancer Res. 3 1997 1261 1266 (Pubitemid 27362386)
26. T.W. Kim, and F. Innocenti Insights, challenges, and future directions in irinogenetics Ther. Drug Monit. 29 2007 265 270 (Pubitemid 47262254)
27. F. Innocenti, D.L. Kroetz, E. Schuetz, M.E. Dolan, J. Ramírez, M. Relling, P. Chen, S. Das, G.L. Rosner, and M.J. Ratain Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics J. Clin. Oncol. 27 2009 2604 2614
28. A. Takakura, A. Kurita, T. Asahara, M. Yokoba, M. Yamamoto, S. Ryuge, S. Igawa, Y. Yasuzawa, J. Sasaki, H. Kobayashi, and N. Masuda Rapid deconjugation of SN-38 glucuronide and adsorption of released free SN-38 by intestinal microorganisms in rat Oncol. Lett. 3 2012 520 524
29. Y. Fujiwara An overview of the recent progress in irinotecan pharmacogenetics Pharmacogenomics 11 2010 391 406
30. A. Sparreboom, M.J. de Jonge, P. de Bruijn, E. Brouwer, K. Nooter, W.J. Loos, R.J. van Alphen, R.H. Mathijssen, G. Stoter, and J. Verweij Irinotecan (CPT-11) metabolism and disposition in cancer patients Clin. Cancer Res. 4 1998 2747 2754 (Pubitemid 28523501)
31. X.-Y. Chu, Y. Kato, K. Ueda, H. Suzuki, K. Niinuma, C.A. Tyson, V. Weizer, J.E. Dabbs, R. Froehlich, C.E. Green, and Y. Sugiyama Biliary excretion mechanism of CPT-11 and its metabolites in humans: involvement of primary active transporters Cancer Res. 58 1998 5137 5143 (Pubitemid 28521174)
32. T. Hamaguchi, T. Doi, T. Eguchi-Nakajima, K. Kato, Y. Yamada, Y. Shimada, N. Fuse, A. Ohtsu, S.-i. Matsumoto, M. Takanashi, and Y. Matsumura Phase I study of NK012, a novel sn-38-incorporating micellar nanoparticle, in adult patients with solid tumors Clin. Cancer Res. 16 2010 5058 5066
33. R. Kurzrock, S. Goel, J. Wheler, D. Hong, S. Fu, K. Rezai, S.K. Morgan-Linnell, S. Urien, S. Mani, I. Chaudhary, M.H. Ghalib, A. Buchbinder, F. Lokiec, and M. Mulcahy Safety, pharmacokinetics, and activity of EZN-2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies Cancer 118 2012 6144 6151
34. J.C. Wang DNA topoisomerases Annu. Rev. Biochem. 54 1985 665 697 (Pubitemid 15073661)
35. Y. Pommier Topoisomerase I inhibitors: camptothecins and beyond Nat. Rev. Cancer 6 2006 789 802 (Pubitemid 44450467)
36. C. Marchand, and Y. Pommier Topoisomerases inhibitors: a paradigm for interfacial inhibition Y. Pommier, DNA Topoisomerases and Cancer 2012 Springer New York 175 184
37. Y. Pommier DNA topoisomerase I inhibitors: chemistry, biology and interfacial inhibition Chem. Rev. 109 2009 2894
38. J.C. Wang Cellular roles of DNA topoisomerases: a molecular perspective Nat. Rev. Mol. Cell Biol. 3 2002 430 440 (Pubitemid 34685700)
39. N.E. Schoemaker, I.E.L.M. Kuppens, W.W.T.B. Huinink, P. Lefebvre, J.H. Beijnen, S. Assadourian, G.-J. Sanderink, and J.H.M. Schellens Phase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumours Cancer Chemother. Pharmacol. 55 2005 263 270 (Pubitemid 40142891)
40. H. Pitot, A. Adjei, J. Reid, J. Sloan, P. Atherton, J. Rubin, S. Alberts, B. Duncan, L. Denis, L. Schaaf, D. Yin, A. Sharma, P. McGovren, L. Miller, and C. Erlichman A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors Cancer Chemother. Pharmacol. 58 2006 165 172
41. R.L. Drengler, J.G. Kuhn, L.J. Schaaf, G.I. Rodriguez, M.A. Villalona-Calero, L.A. Hammond, J. Stephenson, A. Joseph, S. Hodges, M.A. Kraynak, B.A. Staton, G.L. Elfring, P.K. Locker, L.L. Miller, D.D. Von Hoff, and M.L. Rothenberg Phase I and pharmacokinetic trial of oral irinotecan administered daily for 5 days every 3 weeks in patients with solid tumors J. Clin. Oncol. 17 1999 685
42. E.K. Rowinsky, L.B. Grochow, D.S. Ettinger, S.E. Sartorius, B.G. Lubejko, T.-L. Chen, M.K. Rock, and R.C. Donehower Phase I and pharmacological study of the novel topoisomerase i inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks Cancer Res. 54 1994 427 436
43. J.-F. Marier, L. Pheng, M.M. Trinh, H.A. Burris, S. Jones, K. Anderson, S. Warner, and D. Porubek Pharmacokinetics of SN2310, an injectable emulsion that incorporates a new derivative of SN-38 in patients with advanced solid tumors J. Pharm. Sci. 100 2011 4536 4545
44. K. Kobayashi, B. Bouscarel, Y. Matsuzaki, S. Ceryak, S. Kudoh, and H. Fromm pH-dependent uptake of irinotecan and its active metabolite, SN-38, by intestinal cells Int. J. Cancer 83 1999 491 496 (Pubitemid 29489864)
45. P. Tobin, S. Clarke, J.P. Seale, S. Lee, M. Solomon, S. Aulds, M. Crawford, J. Gallagher, T. Eyers, and L. Rivory The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and β-glucuronidase in human colorectal tumours Br. J. Clin. Pharmacol. 62 2006 122 129 (Pubitemid 44195248)
46. J. Rautio, H. Kumpulainen, T. Heimbach, R. Oliyai, D. Oh, T. Jarvinen, and J. Savolainen Prodrugs: design and clinical applications Nat. Rev. Drug Discov. 7 2008 255 270 (Pubitemid 351324639)
47. C. Romain, J.F. Sandrine, D. Chantal, M. Olivier, B. Mohamed, G. Francois, and R. Eric First-in-human phase I and pharmacokinetic study of DTS-108 in patients with advanced carcinomas 2012 ASCO Annual Meeting 2012 American Society of Clinical Oncology
48. Immunomedics Inc. A Phase I Study of IMMU-130 (hMN-14-SN38 Antibody Drug Conjugate) in Patients with Colorectal Cancer 2012 U.S. National Institutes of Health
49. R. Kolhatkar, P. Swaan, and H. Ghandehari Potential oral delivery of 7-ethyl-10-hydroxy-camptothecin (SN-38) using poly(amidoamine) dendrimers Pharm. Res. 25 2008 1723 1729
50. Z. Liu, J.T. Robinson, X. Sun, and H. Dai PEGylated nanographene oxide for delivery of water-insoluble cancer drugs J. Am. Chem. Soc. 130 2008 10876 10877
51. S. Angenault, S. Thirot, F. Schmidt, C. Monneret, B. Pfeiffer, and P. Renard Cancer chemotherapy: a SN-38 (7-ethyl-10-hydroxycamptothecin) glucuronide prodrug for treatment by a PMT (Prodrug monoTherapy) strategy Bioorg. Med. Chem. Lett. 13 2003 947 950 (Pubitemid 36255573)
52. B. Huang, A. Desai, S. Tang, T.P. Thomas, and J.R. Baker The synthesis of a c(RGDyK) targeted SN38 prodrug with an indolequinone structure for bioreductive drug release Org. Lett. 12 2010 1384 1387
53. C.C. Williams, S.H. Thang, T. Hantke, U. Vogel, P.H. Seeberger, J. Tsanaktsidis, and B. Lepenies RAFT-derived polymer-drug conjugates: poly(hydroxypropyl methacrylamide) (hpma)-7-ethyl-10-hydroxycamptothecin (sn-38) conjugates ChemMedChem 7 2012 281 291
54. B. Lundberg Biologically active camptothecin derivatives for incorporation into liposome bilayers and lipid emulsions Anticancer Drug Des. 13 1998 453 461 (Pubitemid 28334032)
55. E.-Y. Kwak, W.-S. Shim, J.-E. Chang, S. Chong, D.-D. Kim, S.-J. Chung, and C.-K. Shim Enhanced intracellular accumulation of a non-nucleoside anti-cancer agent via increased uptake of its valine ester prodrug through amino acid transporters Xenobiotica 42 2012 603 613
56. H. Zhang, J. Wang, W. Mao, J. Huang, X. Wu, Y. Shen, and M. Sui Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: In vitro and in vivo studies J. Control. Release 166 2013 147 158
57. F. Meyer-Losic, C. Nicolazzi, J. Quinonero, F. Ribes, M. Michel, V. Dubois, C. de Coupade, M. Boukaissi, A.-S. Chéné, I. Tranchant, V. Arranz, I. Zoubaa, J.-S. Fruchart, D. Ravel, and J. Kearsey DTS-108, a novel peptidic prodrug of SN38: in vivo efficacy and toxicokinetic studies Clin. Cancer Res. 14 2008 2145 2153 (Pubitemid 351551127)
58. Q. Li, Y. Zu, R. Shi, L. Yao, Y. Fu, Z. Yang, and L. Li Synthesis and antitumor activity of novel 10-substituted camptothecin analogues Bioorg. Med. Chem. 14 2006 7175 7182 (Pubitemid 44403111)
59. S. Jaracz, J. Chen, L.V. Kuznetsova, and I. Ojima Recent advances in tumor-targeting anticancer drug conjugates Bioorg. Med. Chem. 13 2005 5043 5054 (Pubitemid 41039965)
60. R.M. Sharkey, M. Juweid, J. Shevitz, T. Behr, R. Dunn, L.C. Swayne, G.Y. Wong, R.D. Blumenthal, G.L. Griffiths, J.A. Siegel, S.-o. Leung, H.J. Hansen, and D.M. Goldenberg Evaluation of a complementarity-determining region-grafted (humanized) anti-carcinoembryonic antigen monoclonal antibody in preclinical and clinical studies Cancer Res. 55 1995 5935s 5945s
61. S.-J. Moon, S.V. Govindan, T.M. Cardillo, C.A. D'Souza, H.J. Hansen, and D.M. Goldenberg Antibody conjugates of 7-ethyl-10-hydroxycamptothecin (SN-38) for targeted cancer chemotherapy J. Med. Chem. 51 2008 6916 6926
62. S.V. Govindan, T.M. Cardillo, S.-J. Moon, H.J. Hansen, and D.M. Goldenberg CEACAM5-targeted therapy of human colonic and pancreatic cancer xenografts with potent labetuzumab-SN-38 immunoconjugates Clin. Cancer Res. 15 2009 6052 6061
63. T.M. Cardillo, S.V. Govindan, R.M. Sharkey, P. Trisal, and D.M. Goldenberg Humanized anti-Trop-2 IgG-SN-38 conjugate for effective treatment of diverse epithelial cancers: preclinical studies in human cancer xenograft models and monkeys Clin. Cancer Res. 17 2011 3157 3169
64. R.M. Sharkey, S.V. Govindan, T.M. Cardillo, and D.M. Goldenberg Epratuzumab-SN-38: a new antibody-drug conjugate for the therapy of hematologic malignancies Mol. Cancer Ther. 11 2012 224 234
65. E.Y. Kwak, M.K. Choi, S.G. Yang, C.K. Shim, and W.S. Shim Investigation into the efficacy of Val-SN-38, a valine-ester prodrug of the anti-cancer agent SN-38 Biomol. Ther. 20 2012 326 331
66. Y. Zhang, L.C. Gold, Tocopherol-modified therapeutic drug compounds, in, Google Patents, 2007.
67. R. Duncan Polymer therapeutics as nanomedicines: new perspectives Curr. Opin. Biotechnol. 22 2011 492 501
68. R. Duncan, and R. Gaspar Nanomedicine(s) under the microscope Mol. Pharm. 8 2011 2101 2141
69. L. Jorgensen, and H.M. Nielson Delivery Technologies for Biopharmaceuticals: Peptides, Proteins, Nucleic Acids and Vaccines 2009 Wiley Hoboken
70. P. Ebrahimnejad, R. Dinarvand, M.R. Jafari, S.A.S. Tabasi, and F. Atyabi Characterization, blood profile and biodistribution properties of surface modified PLGA nanoparticles of SN-38 Int. J. Pharm. 406 2011 122 127
71. P. Ebrahimnejad, R. Dinarvand, A. Sajadi, M.R. Jaafari, A.R. Nomani, E. Azizi, M. Rad-Malekshahi, and F. Atyabi Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines Nanomedicine 6 2010 478 485
72. B.J. Boyd Characterisation of drug release from cubosomes using the pressure ultrafiltration method Int. J. Pharm. 260 2003 239 247 (Pubitemid 36773921)
73. S. Wallace, J. Li, R. Nation, and B. Boyd Drug release from nanomedicines: selection of appropriate encapsulation and release methodology Drug Deliv. Transl. Res. 2 2012 284 292
74. P. Ebrahimnejad, R. Dinarvand, S.A. Sajadi, F. Atyabi, F. Ramezani, and M.R. Jaafari Preparation and characterization of poly lactide-co-glycolide nanoparticles of SN-38 PDA J. Pharm. Sci. Technol. 63 2009 512 520
75. K.K. Vangara, J.L. Liu, and S. Palakurthi Hyaluronic Acid-decorated PLGA-PEG Nanoparticles for Targeted Delivery of SN-38 to Ovarian Cancer Anticancer research 33 6 2013 2425 2434
76. H. Zhao, B. Rubio, P. Sapra, D. Wu, P. Reddy, P. Sai, A. Martinez, Y. Gao, Y. Lozanguiez, C. Longley, L.M. Greenberger, and I.D. Horak Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers Bioconjug. Chem. 19 2008 849 859 (Pubitemid 351614540)
77. P. Sapra, P. Kraft, F. Pastorino, D. Ribatti, M. Dumble, M. Mehlig, M. Wang, M. Ponzoni, L. Greenberger, and I. Horak Potent and sustained inhibition of HIF-1α and downstream genes by a polyethyleneglycol-SN38 conjugate, EZN-2208, results in anti-angiogenic effects Angiogenesis 14 2011 245 253
78. R. Kurzrock, J. Wheler, D.S. Hong, Z. Guo, M.F. Mulcahy, A.B. Benson, S. Goel, U. Swami, S. Mani, and A. Buchbinder Abstract C216: phase 1, first-in-human, dose-escalation study of EZN-2208, a novel anticancer agent, in patients (pts) with advanced malignancies Mol. Cancer Ther. 8 2009 C216
79. V.P. Torchilin Recent advances with liposomes as pharmaceutical carriers Nat. Rev. Drug Discov. 4 2005 145 160 (Pubitemid 40282557)
80. Y. Sadzuka, H. Takabe, and T. Sonobe Liposomalization of SN-38 as active metabolite of CPT-11 J. Control. Release 108 2005 453 459 (Pubitemid 41608676)
81. A. Pal, S. Khan, Y.-F. Wang, N. Kamath, A.K. Sarkar, A. Ahmad, S. Sheikh, S. Ali, D. Carbonaro, A. Zhang, and I. Ahmad Preclinical safety, pharmacokinetics and antitumor efficacy profile of liposome-entrapped SN-38 formulation Anticancer Res. 25 2005 331 341 (Pubitemid 40470128)
82. E. Kraut, M. Fishman, P. Lorusso, J. Steinberg, J. Nieves, G. Fetterly, I. Darling, S. Wanaski, J. Dul, and J. Sherman Pharmacogenomic and Pharmacokinetic Assessment of Liposome Encapsulated SN-38 (LE-SN38) in Advanced Cancer Patients 2004 2501
83. E.H. Kraut, M.N. Fishman, P.M. Lorusso, M.S. Gordon, E.H. Rubin, A. Haas, G.J. Fetterly, P. Cullinan, J.L. Dul, and J.L. Steinberg Final results of a phase I study of liposome encapsulated SN-38 (LE-SN38): safety, pharmacogenomics, pharmacokinetics, and tumor response ASCO Meeting Abstracts 23 2005 2017
84. S. Wang, T. Ye, B. Yang, X. Yi, and H. Yao 7-Ethyl-10-hydroxycamptothecin proliposomes with a novel preparation method: optimized formulation, characterization and in-vivo evaluation Drug Dev. Ind. Pharm. 39 2013 393 401
85. F. Atyabi, A. Farkhondehfai, F. Esmaeili, and R. Dinarvand Preparation of pegylated nano-liposomal formulation containing SN-38: in vitro characterization and in vivo biodistribution in mice Acta Pharm. 59 2009 133 144
86. J. Gong, M. Chen, Y. Zheng, S. Wang, and Y. Wang Polymeric micelles drug delivery system in oncology J. Control. Release 159 2012 312 323
87. M. Guo, W.-T. Rong, J. Hou, D.-F. Wang, Y. Lu, Y. Wang, S.-Q. Yu, and Q. Xu Mechanisms of chitosan-coated poly(lactic-co-glycolic acid) nanoparticles for improving oral absorption of 7-ethyl-10-hydroxycamptothecin Nanotechnology 24 2013 245101
88. Y. Matsumura Preclinical and clinical studies of NK012, an SN-38-incorporating polymeric micelles, which is designed based on EPR effect Adv. Drug Deliv. Rev. 63 2011 184 192
89. Q. Gu, J.Z. Xing, M. Huang, C. He, and J. Chen SN-38 loaded polymeric micelles to enhance cancer therapy Nanotechnology 23 2012 205101
90. K. Duan, X. Zhang, X. Tang, J. Yu, S. Liu, D. Wang, Y. Li, and J. Huang Fabrication of cationic nanomicelle from chitosan-graft-polycaprolactone as the carrier of 7-ethyl-10-hydroxy-camptothecin Colloids Surf. B Biointerfaces 76 2010 475 482
91. Q. Guo, P. Luo, Y. Luo, F. Du, W. Lu, S. Liu, J. Huang, and J. Yu Fabrication of biodegradable micelles with sheddable poly(ethylene glycol) shells as the carrier of 7-ethyl-10-hydroxy-camptothecin Colloids Surf. B Biointerfaces 100 2012 138 145
92. C.-L. Peng, M.-J. Shieh, M.-H. Tsai, C.-C. Chang, and P.-S. Lai Self-assembled star-shaped chlorin-core poly(É-caprolactone)- poly(ethylene glycol) diblock copolymer micelles for dual chemo-photodynamic therapies Biomaterials 29 2008 3599 3608
93. C.-L. Peng, P.-S. Lai, F.-H. Lin, S. Yueh-Hsiu Wu, and M.-J. Shieh Dual chemotherapy and photodynamic therapy in an HT-29 human colon cancer xenograft model using SN-38-loaded chlorin-core star block copolymer micelles Biomaterials 30 2009 3614 3625
94. H. Kasai, T. Murakami, Y. Ikuta, Y. Koseki, K. Baba, H. Oikawa, H. Nakanishi, M. Okada, M. Shoji, M. Ueda, H. Imahori, and M. Hashida Creation of pure nanodrugs and their anticancer properties Angew. Chem. Int. Ed. 51 2012 10315 10318
95. J. Williams, R. Lansdown, R. Sweitzer, M. Romanowski, R. LaBell, R. Ramaswami, and E. Unger Nanoparticle drug delivery system for intravenous delivery of topoisomerase inhibitors J. Control. Release 91 2003 167 172 (Pubitemid 37288887)
96. B.J. Boyd, D.V. Whittaker, S.-M. Khoo, and G. Davey Hexosomes formed from glycerate surfactants - formulation as a colloidal carrier for irinotecan Int. J. Pharm. 318 2006 154 162 (Pubitemid 43977801)
97. G.L. Banna, E. Collovà, V. Gebbia, H. Lipari, P. Giuffrida, S. Cavallaro, R. Condorelli, C. Buscarino, P. Tralongo, and F. Ferraù Anticancer oral therapy: emerging related issues Cancer Treat. Rev. 36 2010 595 605
98. L. Goff, A. Benson III, P. LoRusso, A. Tan, J. Berlin, L. Denis, R. Benner, D. Yin, and M. Rothenberg Phase I study of oral irinotecan as a single-agent and given sequentially with capecitabine Invest. New Drugs 30 2012 290 298
99. X. Yang, Z. Hu, S.Y. Chan, E. Chan, B.C. Goh, W. Duan, and S. Zhou Novel agents that potentially inhibit irinotecan-induced diarrhea Curr. Med. Chem. 12 2005 1343 1358 (Pubitemid 40711429)
100. N. Vijayalakshmi, A. Ray, A. Malugin, and H. Ghandehari Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation Bioconjug. Chem. 21 2010 1804 1810
101. D.S. Goldberg, N. Vijayalakshmi, P.W. Swaan, and H. Ghandehari G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity J. Control. Release 150 2011 318 325
102. N.T. Huynh, C. Passirani, P. Saulnier, and J.P. Benoit Lipid nanocapsules: a new platform for nanomedicine Int. J. Pharm. 379 2009 201 209
103. B. Heurtault, P. Saulnier, B. Pech, J.-E. Proust, and J.-P. Benoit A novel phase inversion-based process for the preparation of lipid nanocarriers Pharm. Res. 19 2002 875 880 (Pubitemid 34692585)
104. D. Lessard, S. Gori, D. Palusova, L. Courtemanche, D. Le Garrec, C. Benquet, W. Baille, P. Kujawa, L. Juverdianu, D. Smith, S. Taga, and W. Zamboni Antitumor response and pharmacokinetic studies of an orally administered pH-sensitive micellar formulation of SN38 using a polymeric nanodelivery system (SN38-PNDS) in preclinical models AACR Meeting Abstracts 2008 783
105. D. Lessard, L. Luo, D. Le Garrec, D. Smith, Compositions and methods for pH targeted drug delivery, in, Google Patents, 2009.
106. D. Le Garrec, C. Benquet, D. Lessard, M. Parisien, D. Palusova, P. Kujawa, W. Baille, M. Nasser-Eddine, and D. Smith Abstract C218: antitumor activities of a novel oral formulation of SN38 Mol. Cancer Ther. 8 2009 C218
107. G.-M. Seo, R. Rachakatla, S. Balivada, M. Pyle, T. Shrestha, M. Basel, C. Myers, H. Wang, M. Tamura, S. Bossmann, and D. Troyer A self-contained enzyme activating prodrug cytotherapy for preclinical melanoma Mol. Biol. Rep. 39 2012 157 165
108. M.T. Basel, S. Balivada, T.B. Shrestha, G.-M. Seo, M.M. Pyle, M. Tamura, S.H. Bossmann, and D.L. Troyer A cell-delivered and cell-activated SN38-dextran prodrug increases survival in a murine disseminated pancreatic cancer model Small 8 2012 913 920
109. H. Wang, T.B. Shrestha, M.T. Basel, R.K. Dani, G.-M. Seo, S. Balivada, M.M. Pyle, H. Prock, O.B. Koper, P.S. Thapa, D. Moore, P. Li, V. Chikan, D.L. Troyer, and S.H. Bossmann Magnetic-Fe/Fe3O4-nanoparticle-bound SN38 as carboxylesterase-cleavable prodrug for the delivery to tumors within monocytes/macrophages Beilstein J. Nanotechnol. 3 2012 444 455
110. B. Fejerskov, and A.N. Zelikin Substrate mediated enzyme prodrug therapy PLoS One 7 2012 e49619
111. C. Manaspon, S. Hongeng, A. Boongird, and N. Nasongkla Preparation and in vitro characterization of SN-38-loaded, self-forming polymeric depots as an injectable drug delivery system J. Pharm. Sci. 101 2012 3708 3717